Bifogade filer
OncoZenge Reports Positive Stability Results for BupiZenge™ as Key Enabler for the Upcoming Phase III Trial
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
OncoZenge AB (publ), a pharmaceutical company developing innovative treatments for oral pain management, today announced that the three-month stability study results for its BupiZenge™ lozenge are within specifications. The batch was successfully manufactured at Meribel Pharma Solutions in Solna, Sweden, in December 2025 following a technology transfer conducted in collaboration with Molteni Farmaceutici.
This milestone further confirms the manufacturing process for BupiZenge™, OncoZenge's lead product candidate designed to provide targeted, long-lasting relief for cancer patients suffering from oral mucositis.
The positive stability data supports the ongoing development program and paves the way for the upcoming Phase III trial targeting 1st patient in Q2 2026.
"We are thrilled with these expected but confirmatory results, which demonstrate quality and reliability of our production process," said Tuulikki Lindmark, Head of CMC at OncoZenge AB. "This achievement is a testament to the excellent teamwork and dedication from our partners at Meribel Pharma Solutions and Molteni Farmaceutici. We now look forward to receive regulatory confirmation and the opportunity to offer BupiZenge™ to patients in our trial."